XBIO REPORT

FREE WEEKLY BIOTECH STOCK CATALYST REPORTS
CONTACT

Tag: Ameluz Red Light

October 7, 2026

Biofrontera Announces FDA Approval of Ameluz Red Light PDT for the Treatment of Superficial Basal Cell Carcinoma

NASDAQ: $BFRI WOBURN, Mass., Sept. 14, 2026 (GLOBE NEWSWIRE) — Biofrontera Inc. (NASDAQ: BFRI) (“Biofrontera” or the “Company”), a biopharmaceutical company specializing in the development and commercialization of photodynamic therapy (PDT) in dermatology, today… Source: Read More

FDA Acceptance

$BFRI, Ameluz Red Light, Basal Cell Carcinoma, Biofrontera Inc, FDA Approval

Disclaimer: This site is for information only. Not investment advice.

Subscribe For A Premium Report To Maximize Your Returns

The FREE bio tech stock catalyst report ONLY includes companies with catalysts within the current week. Often, this may not be enough time to capture the pre-catalyst stock price movements. For MAX RETURNS. Subscribe to a premium report type below and you will receive reports with a longer outlook, allowing you to discover earlier entries to be positioned before a price move happens. Don’t miss out, maximize your return potential!

Choose your outlook window (each priced accordingly)

30 DAY

60 DAY

90 DAY

120 DAY

UNLIMITED

Get FREE Biotech Stock Catalyst Reports

Email